Clinical development of Abraxane, albumin-bound paclitaxel

Drug Delivery System

Volumn 24, Issue 1, 2009, Pages 38-44

  Yamada, Kazuhiko ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Albumin bound paclitaxel; Nanoparticle; Phase I

Indexed keywords

ALBUMIN; CREMOPHOR; NANOPARTICLE; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; RECOMMENDED DRUG DOSE;

EID: 77953456260     PISSN: 09135006     EISSN: 18812732     Source Type: Journal    
DOI: 10.2745/dds.24.38     Document Type: Article

References (13)

1. van Zuylen L et al.: Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. Anticancer Drugs 11 (5): 331-337, 2000.
2. Weiss RB et al.: Hypersensitivity reactions from taxol. J Clin Oncol 8(7): 1263-1268. 1990.
3. Boer HH et al.: Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis. J Neurooncol 25(1): 49-57. 1995.
4. Windebank AJ: The vehicle for cyclosporine is neurotoxic in vitro. Ann Neurol 41(4): 563-564, 1997.
5. Authier N et al.: Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 887(2): 239-249, 2000.
6. Gianni L et al.: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13(1): 180-190, 1995.
7. Sparreboom A et al.: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59(7): 1454-1457, 1999.
8. Gianni L et al.: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15(5): 1906-1915, 1997.
9. Waugh WN, Trissel LA, Stella VJ: Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 48(7): 1520-1524, 1991.
10. Ibrahim NK. et al.: Phase I and pharmacokinetic study of ABI-007. a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5): 1038-1044, 2002.
11. Gradishar WJ et al.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31): 7794-7803, 2005.
12. Rizvi NA et al.: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 26(4): 639-643, 2008.
13. Gradishar WJ et al.: Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC). Journal of Clinical Oncology. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(No 14S): 635, 2004.